P548 Deep remission: a recurrent feature in patients with Crohn's disease and long term biologic therapy

Vadan, Roxana; Gheorghe, L.; Cerban, Răzvan; Cotruta, Bogdan; Tugui, Letitia; Stanel, I.; Angelescu, C; Băncilă, Ion; Diculescu, Mircea; Gheorghe, Cristian

doi:10.1016/s1873-9946(13)60569-3

Cited by 2 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] A diagnosis of CD was captured for 769 patients, and a diagnosis of UC was provided for 443 patients. 18,20,21 Nine studies were prospective in design, 16,18,19,21,23,24,[27][28][29] and seven were carried out at multiple institutions. 16,17,19,20,23,24,30 No phase IV trials were identi ed for inclusion.…”

Section: Search Resultsmentioning

confidence: 99%

“…22,24 Two conference abstracts used the same cohort and reported rates of DR at different time points, therefore this cohort was only counted one time. 27,28 Ten studies featured only in iximab (IFX), 16, 18, 20-22, 24, 26-29 two used only adalimumab (ADA), 19,23 one study assessed golimumab, 30 and two studies incorporated both IFX and ADA. 17,25 Pineton de Chambrun 2016 reported that 65% of DR patients received concomitant therapy with AZA, whereas only 28% of their non-DR group was receiving concomitant AZA.…”

Section: Search Resultsmentioning

confidence: 99%

“…16, 19-21, 23, 24, 26-29 Rates of DR in biologic naïve patients (Fig. 4) was 36.4% (95% CI: 12.6-69.4%) in 86/229 patients at eight weeks in four studies, 20, 23, 24, 29 39.1% (95% CI: 10.4-78%) in 62/155 patients at 6 months in four studies, 19,21,24,28 47.2% (95% CI: 34.5-60.4%) in 129/284 patients at one year in six studies, 16,19,21,23,24,27 and 46.7% (95% CI: 23.9-71%) in 52/129 patients at two years in three studies. 19,21,26 Funnel plot and Egger's tests did not demonstrate publication bias except for 2 years (Egger's t-value = 8.607, p = 0.037).…”

Section: Deep Remission In Biologic Naïve Patientsmentioning

confidence: 96%

“…Four studies reported a combined 36.4% (95% CI: 12.6-69.4%) rate (86/230 patients) of achieving DR at eight weeks. 20,23,24,29 Four studies reported the rate of DR at six months, 19,21,24,28 with 39.1% (95% CI: 10.4-78.0%), or 62/155 patients, achieving the treatment target ( Fig. 2).…”

Section: Quality Of Studies and Risk Of Biasmentioning

confidence: 99%

“…Crohn's Disease (CD): Ten studies reported rates of DR in 769 patients with CD between eight weeks and 2 years. [17][18][19][20][21][22][25][26][27][28] At eight weeks, one study reported 18.9% DR. 20 17,19,21,22,26 DR in CD was reported at one year by ve studies (Fig. 3) and found to be 48.6% (95% CI: 32.8-64.7%) in 139/293 patients.…”

Section: Achieving Deep Remission In Crohn's Disease and Ulcerative Cmentioning

confidence: 99%

See 4 more Smart Citations

Systematic Review and Meta-analysis:Real-world Data Rates of Deep Remission With Anti-TNFα in Inflammatory Bowel Disease

Alipour

Gulati

Shao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background & Aims Deep remission (DR) is a treatment target in IBD associated with reduced hospitalization and improved outcome. Randomized control trial (RCT) data demonstrates efficacy of anti-TNFα agents in achieving DR; however, RCTs may not be generalizable to clinical practice. In this systematic review with meta-analysis, we use real-world data (RWD) to determine rates of DR in IBD treated with anti-TNFα. Methods We completed a systematic search of MEDLINE and EMBASE on July 8, 2019 with review of major gastrointestinal conference abstracts from 2012-2019. Studies utilizing RWD (data not from phase I-III RCTs) of adult IBD patients treated with anti-TNFα agents were included. DR was defined by clinical and endoscopic remission at minimum. DR was assessed at 8 weeks, 6 months, 1 year, and 2 years.Results 29,033 publications were found on initial search. Fifteen publications, nine manuscripts and six conference abstracts, were included encompassing 1,212 patients (769 Crohn’s disease-CD, 443 ulcerative colitis-UC). Rate of DR was 36.4% (95%-CI: 12.6-69.4%) at eight weeks, 39.1% (95%-CI: 10.4-78%) at six months, 44.4% (95%-CI: 34.6-54.6%) at one year, and 36% (95%-CI: 18.7-58%) at two years. DR in CD at one year was 48.6% (95%-CI: 32.8-64.7%) and in UC was 43.6% (95%-CI: 32.8-55.1%).Conclusions The rate of DR was highest after one year of therapy, in nearly 45% of IBD patients treated with anti-TNFα. Similar rates were achieved between patients with UC and CD. The findings highlight the efficacy of anti-TNFα in real-world setting. Future studies using RWD can determine efficacy of newer IBD therapeutics in routine clinical practice.

show abstract

Section: Search Resultsmentioning

confidence: 99%

Section: Search Resultsmentioning

confidence: 99%

Section: Deep Remission In Biologic Naïve Patientsmentioning

confidence: 96%

Section: Quality Of Studies and Risk Of Biasmentioning

confidence: 99%

Section: Achieving Deep Remission In Crohn's Disease and Ulcerative Cmentioning

confidence: 99%

See 3 more Smart Citations

Systematic Review and Meta-analysis:Real-world Data Rates of Deep Remission With Anti-TNFα in Inflammatory Bowel Disease

Alipour

Gulati

Shao

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease

et al. 2021

View full text Add to dashboard Cite

Background Deep remission (DR) is a treatment target in IBD associated with reduced hospitalization and improved outcome. Randomized control trial (RCT) data demonstrates efficacy of anti-TNFα agents in achieving DR; however, real-world data (RWD) can provide information complementary to RCTs, specifically regarding treatment duration. In this systematic review with meta-analysis, we use real-world data (RWD) to determine rates of DR in IBD treated with anti-TNFα. Methods We completed a systematic search of MEDLINE and EMBASE on July 8, 2019 with review of major gastrointestinal conference abstracts from 2012 to 2019. Studies utilizing RWD (data not from phase I-III RCTs) of adult IBD patients treated with anti-TNFα agents were included. DR was defined by clinical and endoscopic remission at minimum. DR was assessed at 8 weeks, 6 months, 1 year, and 2 years. Risk of bias was assessed with the Newcastle Ottawa Scale. Results 29,033 publications were identified. Fifteen publications, nine manuscripts and six conference abstracts, were included encompassing 1212 patients (769 Crohn’s disease-CD, 443 ulcerative colitis-UC), and analyzed using Comprehensive Meta-Analysis. Rate of DR was 36.4% (95% CI 12.6–69.4%) at 8 weeks, 39.1% (95% CI 10.4–78%) at 6 months, 44.4% (95% CI 34.6–54.6%) at 1 year, and 36% (95% CI 18.7–58%) at 2 years. DR in CD at 1 year was 48.6% (95% CI 32.8–64.7%) and in UC was 43.6% (95% CI 32.8–55.1%). Conclusions The rate of DR was highest after 1 year of therapy, in nearly 45% of IBD patients treated with anti-TNFα. Similar rates were achieved between patients with UC and CD. The findings highlight the efficacy of anti-TNFα in real-world setting. Future studies using RWD can determine efficacy of newer IBD therapeutics in routine clinical practice.

show abstract

P548 Deep remission: a recurrent feature in patients with Crohn's disease and long term biologic therapy

Cited by 2 publications

References 0 publications

Systematic Review and Meta-analysis:Real-world Data Rates of Deep Remission With Anti-TNFα in Inflammatory Bowel Disease

Systematic Review and Meta-analysis:Real-world Data Rates of Deep Remission With Anti-TNFα in Inflammatory Bowel Disease

Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease

Contact Info

Product

Resources

About